Skip to content

Study · Systematic review · n = 39,204 · 2026

7 results

Effects of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a systematic review and meta-analysis.

Marzano F, Paolillo S, Gargiulo P, Cotticelli C, Di Santo M, Nardi E, Abbellito GM, Liccardi L, Perrone Filardi F, Bruzzese D, Perrone Filardi P

Cardiovascular diabetology25 May 2026

PMID42186086 (opens in a new tab)PMCIDPMC13479731 (opens in a new tab)DOI10.1186/s12933-026-03215-y (opens in a new tab)PepBankPUB-42186086
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In pooled RCTs across the cardio-kidney-metabolic continuum, semaglutide reduced all-cause mortality versus placebo (HR 0.84).

    In plain wordsIn pooled trials of people with heart, kidney or metabolic disease, semaglutide lowered the chance of death from any cause compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseAll-cause mortality
    Study

    n = 39,204

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR all-cause mortality
    0.84 HR
    vs placebo

    Source sentences

    Summary
    In patients treated with semaglutide a significant reduction of all-cause (HR, 0.84; 95% CI, 0.77-0.92; p = 0.0001)
    2 context sentences
    Summary · context
    A systematic literature search was conducted to identify all eligible RCTs comparing the prognostic effects of semaglutide with placebo across diverse patient populations.
    Summary · context
    Eight trials encompassing 39,204 patients were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In pooled RCTs across the cardio-kidney-metabolic continuum, semaglutide reduced cardiovascular mortality versus placebo (HR 0.83).

    In plain wordsIn pooled trials of people with heart, kidney or metabolic disease, semaglutide lowered the chance of death from heart causes compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseCardiovascular mortality
    Study

    n = 39,204

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR cardiovascular mortality
    0.83 HR
    vs placebo

    Source sentences

    Summary
    CV mortality (HR, 0.83; 95% CI, 0.72-0.95; p = 0.0078)
    2 context sentences
    Summary · context
    A systematic literature search was conducted to identify all eligible RCTs comparing the prognostic effects of semaglutide with placebo across diverse patient populations.
    Summary · context
    Eight trials encompassing 39,204 patients were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In pooled RCTs across the cardio-kidney-metabolic continuum, semaglutide reduced major adverse cardiovascular events versus placebo (HR 0.82).

    In plain wordsIn pooled trials of people with heart, kidney or metabolic disease, semaglutide lowered major heart and blood vessel events compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseMajor adverse cardiovascular events
    Study

    n = 39,204

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR MACE
    0.82 HR
    vs placebo

    Source sentences

    Summary
    major adverse CV events (MACE, HR, 0.82; 95% CI, 0.77-0.87; p < 0.0001)
    2 context sentences
    Summary · context
    A systematic literature search was conducted to identify all eligible RCTs comparing the prognostic effects of semaglutide with placebo across diverse patient populations.
    Summary · context
    Eight trials encompassing 39,204 patients were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In pooled RCTs across the cardio-kidney-metabolic continuum, semaglutide reduced kidney outcomes versus placebo (HR 0.83).

    In plain wordsIn pooled trials of people with heart, kidney or metabolic disease, semaglutide lowered the rate of kidney outcomes compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseKidney outcomes
    Study

    n = 39,204

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    HR kidney outcomes
    0.83 HR
    vs placebo

    Source sentences

    Summary
    kidney outcomes (HR, 0.83; 95% CI, 0.73-0.95; p = 0.0080)
    2 context sentences
    Summary · context
    A systematic literature search was conducted to identify all eligible RCTs comparing the prognostic effects of semaglutide with placebo across diverse patient populations.
    Summary · context
    Eight trials encompassing 39,204 patients were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In pooled RCTs across the cardio-kidney-metabolic continuum, semaglutide reduced nonfatal myocardial infarction versus placebo (HR 0.75).

    In plain wordsIn pooled trials of people with heart, kidney or metabolic disease, semaglutide lowered non-fatal heart attacks compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseNonfatal myocardial infarction
    Study

    n = 39,204

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR nonfatal MI
    0.75 HR
    vs placebo

    Source sentences

    Summary
    nonfatal myocardial infarction (MI, HR, 0.75; 95% CI, 0.68-0.84; p < 0.0001)
    2 context sentences
    Summary · context
    A systematic literature search was conducted to identify all eligible RCTs comparing the prognostic effects of semaglutide with placebo across diverse patient populations.
    Summary · context
    Eight trials encompassing 39,204 patients were included.
  6. 06HumanSystematic reviewEfficacy outcome

    In pooled RCTs across the cardio-kidney-metabolic continuum, semaglutide reduced worsening heart failure versus placebo (HR 0.84).

    In plain wordsIn pooled trials of people with heart, kidney or metabolic disease, semaglutide lowered worsening heart failure compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseWorsening heart failure
    Study

    n = 39,204

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR worsening heart failure
    0.84 HR
    vs placebo

    Source sentences

    Summary
    worsening heart failure (HF, HR, 0.84; 95% CI, 0.73-0.98; p = 0.0245)
    2 context sentences
    Summary · context
    A systematic literature search was conducted to identify all eligible RCTs comparing the prognostic effects of semaglutide with placebo across diverse patient populations.
    Summary · context
    Eight trials encompassing 39,204 patients were included.
  7. 07HumanSystematic reviewEfficacy outcome

    In pooled RCTs across the cardio-kidney-metabolic continuum, semaglutide had no significant effect on nonfatal stroke versus placebo.

    In plain wordsIn pooled trials of people with heart, kidney or metabolic disease, semaglutide did not significantly change non-fatal stroke compared with placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeNonfatal stroke
    Study

    n = 39,204

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant effects were observed for nonfatal stroke.
    2 context sentences
    Summary · context
    A systematic literature search was conducted to identify all eligible RCTs comparing the prognostic effects of semaglutide with placebo across diverse patient populations.
    Summary · context
    Eight trials encompassing 39,204 patients were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.